Fistulizing Crohn's disease.

Fistulas are common in Crohn's disease. A population-based study has shown a cumulative risk of 33% after 10 years and 50% after 20 years. Perianal fistulas were the most common (54%). Medical therapy is the main option for perianal fistula once abscesses, if present, have been drained, and should include antibiotics (both ciprofloxacin and metronidazole) and immunomodulators. Infliximab should be reserved for refractory patients. Surgery is often necessary for internal fistulas.

Extraintestinal manifestations of Crohn's disease.

In each case of extraintestinal manifestations of Crohn's disease, active disease, if present, should be treated to induce remission, which may positively influence the course of most concomitant extraintestinal manifestations. For some extraintestinal manifestations, however, a specific treatment should be introduced. This latter part of disease management will be discussed in this chapter, in particular for pyoderma gangrenosum, uveitis, spondylarthropathy--axial arthropathy--and primarysclerosing cholangitis, which have also been described in quiescent Crohn's disease. Few new drugs for the treatment of extraintestinal manifestations of Crohn's disease have been developed in the past and only the role of infliximab has increased in Crohn's disease-related extraintestinal manifestations. Drugs specifically aimed at this treatment, stemming from a few randomized controlled studies or case series, are sulfasalazine, 5-ASA, corticosteroids, azathioprine or 6-mercaptopurine, methotrexate, infliximab, dapsone and cyclosporine or tacrolimus.

Appropriateness of therapy for active Crohn's disease: results of a multidisciplinary international expert panel-EPACT II

The increasing number of trials testing management strategies for luminal Crohn's disease (CD) has not fitted all the gaps in our knowledge and thus, in clinical. practice, many decisions for CD patients have to be taken without the benefit of high-quality evidence. Methods: A multidisciplinary European expert panel used the RAND Appropriateness Method to develop and rate explicit criteria for the management of individual patients with active, steroid-dependent (ST-D) and steroid-refractory (ST-R) CD. Results: Overall., 296 indications pertaining to mild-to-moderate, severe, ST-D, and ST-R CD were rated. In anti-TNF naive patients, budesonide and prednisone were found to be appropriate for mild-moderate CD, and infliximab (IFX) was appropriate when these had previously failed or had not been tolerated. In patients with a prior successful treatment by IFX, this drug, with or without co-administration of a thiopurine analog, was favoured. Other anti-TNFs were appropriate in the presence of intolerance or resistance to IFX. High-dose steroids, IFX or adlimumab were appropriate in severe active CD. For the 105 indications for ST-D or ST-R disease, the panel considered the thiopurine analogs, methotrexate, IFX, adalimumab, and surgery for limited resection, to be appropriate, depending on the outcome of prior therapies. Anti-TNFs were generally considered appropriate in ST-R. Conclusion: Steroids, including budesonide for mild-to-moderate CD, remain the first-line therapy for active luminal CD. Anti-TNFs, in particular IFX as shown by the amount of available evidence, remain the second-line therapy for most indications. Thiopurine analogs, methotrexate and anti-TNFs are favoured in ST-D patients and ST-R patients. (C) 2009 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

El Sentido de la Vida y el Deseo de Adelantar la Muerte en pacientes con procesos avanzados de enfermedad

El deseo de adelantar la muerte (DAM) no es infrecuente en la población paliativa o con cáncer avanzado. Las evidencias actuales muestran el DAM como una respuesta reactiva al sufrimiento multidimensional propio del paciente en con procesos avanzados de enfermedad. Tras estudiar los factores relacionados con el DAM, se ha observado que la variable sentido de la vida (SV), desempeña un rol importante en relación al desencadenamiento del DAM. Hasta el momento se han publicado diversas intervenciones dirigidas a ayudar a los pacientes en la búsqueda o mejora de SV en el tramo final de sus vidas. Sin embargo no se ha evaluado la eficacia de estas intervenciones sobre el DAM. El objetivo principal del presente estudio es evaluar, en una población de pacientes en cuidados paliativos, la efectividad de una intervención de mejora del SV para disminuir el eventual DAM. El estudio se desarrollará en tres fases. En primer lugar se realizará una revisión sistemática integrativa de las intervenciones publicadas para mejorar el SV y posterior selección de la terapia más adecuada de acuerdo con las evidencias halladas. En segundo lugar se hará la adaptación transcultural y validación de un instrumento de medida de SV, el Meaning in Life Questionnaire (MLQ). Por último se llevará a cabo la implementación de la intervención escogida y evaluación de su efectividad para disminuir el DAM, mediante un estudio de diseño pre-post, en pacientes oncológicos ingresados en la unidad de cuidados paliativos. Este trabajo aportará también los resultados preliminares de la revisión sistemática integrativa de las intervenciones de SV.

Factors associated with durable response to infliximab in Crohn's disease 5 years and beyond : a multicenter international cohort

BACKGROUND: Infliximab (IFX) has been used for over a decade worldwide. Less is known about the natural history of IFX use beyond a few years and which patients are more likely to sustain benefits. METHODS: Patients with Crohn's disease (CD) exposed to IFX from Massachusetts General Hospital, Boston, Saint-Antoine Hospital, Paris, and the Swiss IBD Cohort Study were identified through retrospective and prospective data collection, complemented by chart abstraction of electronic medical records. We compared long-term users of IFX (>5 yr of treatment, long-term users of infliximab [LTUI]), with non-LTUI patients to identify prognostic factors. RESULTS: We pooled data on 1014 patients with CD from 3 different databases, of whom 250 were defined as LTUI. The comparison group comprised 290 patients with CD who discontinued IFX: 48 primary nonresponses, 95 loss of responses, and 147 adverse events. Factors associated with LTUI were colonic involvements and an earlier age at the start of IFX. The prevalence of active smokers and obese patients differed markedly, but inversely, between American and European centers but did not impact outcome. The discontinuation rate was stable around 3% to 6%, each year from years 3 to 10. CONCLUSIONS: Young age at start of IFX and colonic CD are factors associated with a beneficial long-term use of IFX. After 5 years of IFX, there is still a 3% to 5% discontinuation rate annually. Several factors associated with a good initial response such as nonsmoker and shorter disease duration at IFX initiation do not seem associated with a longer term response.

Personalidad premórbida y factores de riesgo en la enfermedad de Alzheimer

El presente artículo hace un repaso de los principales estudios respecto a los factores de riesgo para la enfermedad de Alzheimer, priorizando los factores psicosociales y especialmente los que se refieren a la personalidad premórbida. Entre los factores psicosociales de riesgo, aparecen como los más destacados un bajo nivel educativo y una actividad-relación social restringida. Necesidad de protección, tutelaje y dependencia de otras personas, relación social e interpersonal restringida e introversión, son los elementos de riesgo más relevantes para la personalidad premórbida. Los factores que aparecen en los estudios mencionados tienen relación con la hipótesis de trabajo de la investigación que se desarrolla actualmente, acerca de los perfiles de riesgo en la personalidad premórbida. Esta hipótesis los sitúa en el campo de lo emocional y de la relación interpersonal: fragilidad de la identidad personal y sostenimiento del yo a través de una relación simbiótica con el otro.

La reaparición de una olvidada enfermedad en la cavidad oral: la sífilis

La sífilis es una enfermedad de transmisión sexual (ETS) producida por el Treponema pallidum, que infecta principalmente a seres humanos y que es capaz de invadir casi cualquier órgano del cuerpo. Su infección facilita la transmisión de otras ETS. Desde finales de la última década hasta la actualidad, han ido apareciendo sucesivos brotes de sífilis en la mayor parte de países de la Europa Occidental. La sífilis, junto con otras ETS, es una enfermedad de declaración obligatoria en los países de la Unión Europea. Concretamente en España, la infonnación epidemiológica a nivel estatal se obtiene a través del Sistema de Enfemledades de Declaración Obligatoria (EDO) y del Sistema de Información Microbiológica (SIM), que recopila infonnación de una red de 46 laboratorios centinela situados en 12 Comunidades Autónomas. Las ETS sometidas a vigilancia epidemiológica son la infección gonocócica, la sífilis y la sífilis congénita, todas ellas de declaración numérica semanal. Con esta información se ha podido apreciar en los últimos años un incremento en los casos de sífilis y gonococia notificados en España (las tasas de sífilis por 100.000 habitantes en el año 1999 fueron de 1,69 y en el 2007 de 4,38 notificadas al sistema EDO). En este artículo revisamos el resurgimiento y la evolución de esta enfermedad infecciosa en ocho países europeos, a la vez que pretendemos llamar la atención a los dentistas acerca del papel que deben desempeñar en el diagnóstico de la enfennedad y en la derivación a centros de control de infecciones de transmisión sexual

Efectividad de la intervención psicosocial en pacientes con enfermedad avanzada y final de vida

Objetivos: Demostrar la efectividad de la intervención psicosocial en la atención integral a personas con enfermedades avanzadas. Método: Se ha evaluado la presencia y evolución de parámetros psicológicos y espirituales de 8.964 pacientes, visitados por 117 profesionales de 29 equipos en un estudio de diseño cuasi-experimental, prospectivo, multcéntrico de un solo grupo pre-test post-test. Resultados: Los resultados muestran mejoras significativas en parámetros como ansiedad (RL 657,64; p<0,001), malestar emociona (RL 757,44; p<0,001), sentido de la vida (RL 248,30; p<0,001) y sentimientos de paz y perdón (RL 190,94; p<0,001). Conclusiones: El efecto positivo de la intervención psicosocial en la reducción de los parámetros psicológicos y espirituales evaluados sugiere que esta es eficaz en el contexto de la atención a personas con enfermedades avanzadas.

La Enfermedad a lo largo de la historia. Un punto de mira entre la biología y la simbología

Las enfermedades tienen sus propios ritmos que se van modificando a lo largo de los siglos; cada sociedad construye su forma de pensar y sentir las enfermedades. La interdependencia entre las condiciones biológicas y sociales de la vida civilizada, ha ocasionado que cada momento histórico viva de forma distinta la enfermedad. El objetivo de este artículo es reflexionar sobre la forma de ver y vivir la enfermedad en Occidente, a lo largo de la historia, centrándonos especialmente en la creencia, surgida a partir del siglo XVIII, que el progreso humano erradicaría la enfermedad. Las raíces de la forma de sentir la enfermedad en el Occidente de inicios del siglo XXI deben buscarse en los orígenes griegos y judeo-cristianos, que se continúan a lo largo de la Edad Media, hasta que con la llegada de la Modernidad se produce un giro desde la búsqueda de la eternidad en el otro mundo, hacia un caminar a la inmortalidad en la tierra. En los inicios del siglo XXI, el hombre post-moderno traslada la crisis de pensamiento vigente al campo de la salud, ello plantean tensiones que se hacen patentes en la forma de vivir y atender la enfermedad

La Enfermedad a lo largo de la historia. Un punto de mira entre la biología y la simbología

Las enfermedades tienen sus propios ritmos que se van modificando a lo largo de los siglos; cada sociedad construye su forma de pensar y sentir las enfermedades. La interdependencia entre las condiciones biológicas y sociales de la vida civilizada, ha ocasionado que cada momento histórico viva de forma distinta la enfermedad. El objetivo de este artículo es reflexionar sobre la forma de ver y vivir la enfermedad en Occidente, a lo largo de la historia, centrándonos especialmente en la creencia, surgida a partir del siglo XVIII, que el progreso humano erradicaría la enfermedad. Las raíces de la forma de sentir la enfermedad en el Occidente de inicios del siglo XXI deben buscarse en los orígenes griegos y judeo-cristianos, que se continúan a lo largo de la Edad Media, hasta que con la llegada de la Modernidad se produce un giro desde la búsqueda de la eternidad en el otro mundo, hacia un caminar a la inmortalidad en la tierra. En los inicios del siglo XXI, el hombre post-moderno traslada la crisis de pensamiento vigente al campo de la salud, ello plantean tensiones que se hacen patentes en la forma de vivir y atender la enfermedad

Postsurgical Prophylaxis in Crohn's Disease: Which Patients, Which Agents?

NlmCategory="UNASSIGNED">Crohn's disease (CD) evolution is characterized by increasing proportions of patients developing complications such as strictures, abscesses and fistulas that require surgical management. After resection of a diseased intestinal segment, CD recurrence concerns up to 60% of patients within a year post surgery. The mucosa just above the site of the intestinal anastomosis is at particularly high risk of relapse. Prophylactic medical therapy to prevent recurrence has been shown to be effective with a variety of medications, but the recurrence rate remains high, demanding that a better risk stratification of patients be achieved. Recognized risk factors for postsurgical CD recurrence include young age at diagnosis and at surgery, smoking, need for repeated surgeries and penetrating disease. These patients require full dose immunosuppressive or anti-tumor necrosis factor (anti-TNF) therapy, which should be initiated in the immediate postoperative period, to prevent the onset of an inflammatory activity in the bowel. Systematic follow-up by endoscopy to monitor treatment benefit should also be part of the management, as endoscopic recurrence heralds clinical relapse in these patients. The role of noninvasive markers of mucosal inflammation, such as stool calprotectin levels, show promise to complete this monitoring. Although the efficacy of mesalazine and imidazole antibiotics has been long recognized, more aggressive approaches, such as thiopurines and anti-TNF antibodies, have shown higher efficacies in direct comparison trials. The potential place of anti-homing agents is not yet defined, but these agents should in principle be of interest for this prophylactic indication due to their mode of action and interesting side-effect profile. The current recommendations are based on a step-up approach that includes immunosuppressors and/or imidazole antibiotics, followed by an anti-TNF agent, such as infliximab and adalimumab, both already tested in randomized trials in this indication. When endoscopic recurrence is identified during follow-up, upscaling to anti-TNF or dose escalation is advocated.

High rates of smoking especially in female Crohn's disease patients and low use of supportive measures to achieve smoking cessation : Data from the SwissIBD cohort study

BACKGROUND AND AIMS: Smoking is a crucial environmental factor in inflammatory bowel disease (IBD). However, knowledge on patient characteristics associated with smoking, time trends of smoking rates, gender differences and supportive measures to cease smoking provided by physicians is scarce. We aimed to address these questions in Swiss IBD patients. METHODS: Prospectively obtained data from patients participating in the Swiss IBD cohort study was analysed and compared to the general Swiss population (GSP) matched by age, sex and year. RESULTS: Among a total of 1770 IBD patients analysed (49.1% male), 29% are current smokers. More than twice as many patients with Crohn's disease (CD) are active smokers compared to ulcerative colitis (UC, 39.6% vs. 15.3%, p<0.001). In striking contrast to the GSP, significantly more women than men with CD smoke (42.8% vs. 35.8%, p=0.025), with also an overall significantly increased smoking rate compared to the GSP in women but not men. The vast majority of smoking IBD patients (90.5%) claim to never have received any support to achieve smoking cessation, significantly more in UC compared to CD. We identify a significantly negative association of smoking and primary sclerosing cholangitis, indicative of a protective effect. Psychological distress in CD is significantly higher in smokers compared to non-smokers, but does not differ in UC CONCLUSIONS: Despite well-established detrimental effects, smoking rates in CD are alarmingly high with persistent and stagnating elevations compared to the GSP, especially in female patients. Importantly, there appears to be an unacceptable underuse of supportive measures to achieve smoking cessation.

Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease.

BACKGROUND: The impact of early treatment with immunomodulators (IM) and/or TNF antagonists on bowel damage in Crohn's disease (CD) patients is unknown. AIM: To assess whether 'early treatment' with IM and/or TNF antagonists, defined as treatment within a 2-year period from the date of CD diagnosis, was associated with development of lesser number of disease complications when compared to 'late treatment', which was defined as treatment initiation after >2 years from the time of CD diagnosis. METHODS: Data from the Swiss IBD Cohort Study were analysed. The following outcomes were assessed using Cox proportional hazard modelling: bowel strictures, perianal fistulas, internal fistulas, intestinal surgery, perianal surgery and any of the aforementioned complications. RESULTS: The 'early treatment' group of 292 CD patients was compared to the 'late treatment' group of 248 CD patients. We found that 'early treatment' with IM or TNF antagonists alone was associated with reduced risk of bowel strictures [hazard ratio (HR) 0.496, P = 0.004 for IM; HR 0.276, P = 0.018 for TNF antagonists]. Furthermore, 'early treatment' with IM was associated with reduced risk of undergoing intestinal surgery (HR 0.322, P = 0.005), and perianal surgery (HR 0.361, P = 0.042), as well as developing any complication (HR 0.567, P = 0.006). CONCLUSIONS: Treatment with immunomodulators or TNF antagonists within the first 2 years of CD diagnosis was associated with reduced risk of developing bowel strictures, when compared to initiating these drugs >2 years after diagnosis. Furthermore, early immunomodulators treatment was associated with reduced risk of intestinal surgery, perianal surgery and any complication.